
{
  "Company Overview": {
    "Name": "Glenmark Life Sciences Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs & Formln",
    "Business Description": "A leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.",
    "Market Position": "Subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 12,416 Cr.",
    "Current Price": "₹ 1,013",
    "High/Low": "₹ 1,335 / ₹ 645",
    "P/E Ratio": 29.3,
    "Book Value": "₹ 207",
    "Dividend Yield": "2.22 %",
    "ROCE": "28.1 %",
    "ROE": "21.1 %",
    "Face Value": "₹ 2.00",
    "Debt-to-Equity Ratio": null //Not explicitly provided, needs further analysis from balance sheet data.

  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [562, 522, 514, 490, 509, 541, 621, 578, 595, 573, 537, 589, 507],
      "Expenses": [394, 376, 372, 343, 366, 395, 415, 385, 428, 400, 395, 429, 373],
      "Operating Profit": [167, 146, 142, 147, 144, 145, 206, 193, 167, 173, 141, 159, 134],
      "OPM %": ["30%", "28%", "28%", "30%", "28%", "27%", "33%", "33%", "28%", "30%", "26%", "27%", "27%"],
      "Other Income": [2, 4, 5, 9, 10, 7, 3, 2, 5, 2, 3, 5, 9],
      "Interest": [7, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],
      "Depreciation": [10, 10, 10, 10, 10, 11, 12, 13, 13, 13, 15, 14, 15],
      "Profit before tax": [153, 140, 138, 146, 144, 141, 198, 182, 159, 161, 130, 150, 127],
      "Tax %": ["24%", "26%", "28%", "26%", "26%", "26%", "26%", "26%", "25%", "26%", "24%", "26%", "25%"],
      "Net Profit": [115, 104, 99, 109, 107, 105, 146, 135, 119, 119, 98, 111, 95],
      "EPS in Rs": [9.40, 8.46, 8.07, 8.87, 8.72, 8.57, 11.95, 11.05, 9.69, 9.69, 7.99, 9.10, 7.78]
    },
    "Annual Results": {
      "Sales": [0, 886, 1537, 1885, 2123, 2161, 2283, 2205],
      "Expenses": [0, 638, 1064, 1294, 1506, 1518, 1608, 1597],
      "Operating Profit": [0, 248, 473, 592, 617, 643, 675, 608],
      "OPM %": ["-4%", "28%", "31%", "31%", "29%", "30%", "30%", "28%"],
      "Other Income": [0, 0, 11, 0, 14, 28, 11, 19],
      "Interest": [0, 1, 34, 88, 28, 1, 2, 1],
      "Depreciation": [0, 19, 29, 33, 38, 42, 53, 57],
      "Profit before tax": [0, 228, 421, 471, 565, 629, 631, 568],
      "Tax %": ["4200%", "14%", "26%", "25%", "26%", "26%", "25%"],
      "Net Profit": [0, 196, 313, 352, 419, 467, 471, 424],
      "EPS in Rs": [-430.00, 997.86, 1597.37, 358.74, 34.17, 38.11, 38.43, 34.56]
    },
    "Balance Sheet Highlights": {
      "Equity Capital": [0.01, 2, 2, 2, 25, 25, 25, 25],
      "Reserves": [-1, 86, 400, 751, 2030, 2114, 2308, 2514],
      "Borrowings": [0, 0, 0, 0, 3, 19, 17, 16],
      "Other Liabilities": [1, 1387, 1324, 1244, 414, 545, 501, 530],
      "Total Liabilities": [0, 1475, 1726, 1997, 2471, 2702, 2850, 3085],
      "Fixed Assets": [0, 456, 546, 573, 590, 781, 805, 821],
      "CWIP": [0, 80, 11, 14, 97, 62, 106, 141],
      "Investments": [0, 0, 0, 0, 0, 0, 0, 0],
      "Other Assets": [0, 939, 1169, 1410, 1784, 1860, 1939, 2122],
      "Total Assets": [0, 1475, 1726, 1997, 2471, 2702, 2850, 3085]
    },
    "Cash Flow Summaries": {
      "Cash from Operating Activity": [-0, 10, 195, 388, 598, 306, 414],
      "Cash from Investing Activity": [0, -9, -51, -69, -122, -147, -116],
      "Cash from Financing Activity": [0, 1, -137, -214, -79, -388, -279],
      "Net Cash Flow": [0, 2, 8, 106, 397, -228, 18]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth (10 Years)": null, 
      "Compounded Sales Growth (5 Years)": "21%",
      "Compounded Sales Growth (3 Years)": "7%",
      "Compounded Sales Growth (TTM)": "-6%",
      "Compounded Profit Growth (10 Years)": null,
      "Compounded Profit Growth (5 Years)": "19%",
      "Compounded Profit Growth (3 Years)": "10%",
      "Compounded Profit Growth (TTM)": "-16%",
      "Stock Price CAGR (10 Years)": null,
      "Stock Price CAGR (5 Years)": null,
      "Stock Price CAGR (3 Years)": "19%",
      "Stock Price CAGR (1 Year)": "57%"
    },
    "Liquidity Ratios": null, // Requires further calculation from Balance Sheet data
    "Profitability Ratios": {
      "ROCE (10 Years)": null,
      "ROCE (5 Years)": null,
      "ROCE (3 Years)": null,
      "ROCE (Last Year)": "28%",
      "ROE (10 Years)": null,
      "ROE (5 Years)": "31%",
      "ROE (3 Years)": "24%",
      "ROE (Last Year)": "21%"
    },
    "Valuation Ratios": {
      "P/E Ratio": 29.3,
      "Price to Book": null // Needs calculation
    },
    "Other Ratios": {
      "Debtor Days": [44, 185, 152, 120, 116, 136, 122],
      "Inventory Days": [162, 441, 227, 214, 185, 224, 251],
      "Days Payable": [41, 201, 111, 92, 110, 158, 139],
      "Cash Conversion Cycle": [165, 424, 268, 241, 190, 202, 235],
      "Working Capital Days": [-2059, -186, -37, 12, 150, 177, 188]
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Sun Pharma.Inds.", "CMP": 1808.85, "P/E": 38.73, "Mar Cap": 434003.71, "Div Yld": 0.75, "NP Qtr": 3037.33, "Qtr Profit Var": 27.86, "Sales Qtr": 13291.39, "Qtr Sales Var": 9.01, "ROCE": 17.32},
      {"Name": "Cipla", "CMP": 1472.05, "P/E": 25.81, "Mar Cap": 118884.82, "Div Yld": 0.88, "NP Qtr": 1305.01, "Qtr Profit Var": 15.18, "Sales Qtr": 7051.02, "Qtr Sales Var": 5.58, "ROCE": 22.80},
      {"Name": "Mankind Pharma", "CMP": 2805.20, "P/E": 56.07, "Mar Cap": 112393.74, "Div Yld": 0.00, "NP Qtr": 634.43, "Qtr Profit Var": 34.84, "Sales Qtr": 2529.74, "Qtr Sales Var": 11.91, "ROCE": 24.57},
      {"Name": "Dr Reddy's Labs", "CMP": 1343.65, "P/E": 21.00, "Mar Cap": 112115.62, "Div Yld": 0.60, "NP Qtr": 1341.90, "Qtr Profit Var": -15.28, "Sales Qtr": 8038.20, "Qtr Sales Var": 16.45, "ROCE": 26.53},
      {"Name": "Lupin", "CMP": 2150.70, "P/E": 37.36, "Mar Cap": 98114.41, "Div Yld": 0.37, "NP Qtr": 859.48, "Qtr Profit Var": 74.12, "Sales Qtr": 5672.73, "Qtr Sales Var": 12.59, "ROCE": 15.72},
      {"Name": "Zydus Lifesci.", "CMP": 973.50, "P/E": 22.90, "Mar Cap": 97956.88, "Div Yld": 0.31, "NP Qtr": 920.20, "Qtr Profit Var": 13.62, "Sales Qtr": 5237.00, "Qtr Sales Var": 19.87, "ROCE": 22.34},
      {"Name": "Aurobindo Pharma", "CMP": 1241.70, "P/E": 19.96, "Mar Cap": 72756.00, "Div Yld": 0.36, "NP Qtr": 816.95, "Qtr Profit Var": 8.65, "Sales Qtr": 7796.07, "Qtr Sales Var": 7.99, "ROCE": 14.10}
    ],
    "Median": {
      "CMP": 78,
      "P/E": 33.34,
      "Mar Cap": 2869.55,
      "Div Yld": 0.05,
      "NP Qtr": 17.27,
      "Qtr Profit Var": 19.36,
      "Sales Qtr": 188.19,
      "Qtr Sales Var": 9.43,
      "ROCE": 14.1
    }
  },
  "Other Insights": {
    "Pros": [
      "Company is almost debt free.",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 23.7%",
      "Company has been maintaining a healthy dividend payout of 76.8%"
    ],
    "Cons": [
      "The pros and cons are machine generated.",
      "Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis."
    ],
    "Notes": [
      "Prior to 2019 API business was an integral part of Glenmark Pharma (GPL). It was separated out of GPL into GLS through a Business Transfer Agreement in Jan 2019.",
      "GLS was listed on NSE & BSE in FY22.",
      "The classifications might have changed from Sep'2022 onwards.",
      "The new XBRL format added more details from Sep'22 onwards.",
      "Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes."
    ],
    "Company Name Change": "Company name changed from Glenmark to Alivus Life Sciences on 17 Dec"
  },
  "Shareholding Pattern": {
    "Quarterly": {
      "Promoters": [82.85, 82.85, 82.85, 82.85, 82.85, 82.85, 82.85, 82.85, 82.85, 82.85, 82.85, 75.00],
      "FIIs": [8.32, 8.12, 7.58, 6.04, 4.45, 3.28, 3.27, 4.39, 4.57, 5.01, 4.81, 7.85],
      "DIIs": [0.47, 0.56, 0.79, 0.79, 0.08, 0.00, 0.58, 0.64, 0.74, 1.41, 1.57, 4.16],
      "Public": [8.36, 8.47, 8.78, 10.31, 12.62, 13.86, 13.30, 12.13, 11.84, 10.73, 10.76, 12.99]
    },
    "Yearly": {
      "Promoters": [82.85, 82.85, 82.85, 75.00],
      "FIIs": [8.12, 3.28, 5.01, 7.85],
      "DIIs": [0.56, 0.00, 1.41, 4.16],
      "Public": [8.47, 13.86, 10.73, 12.99]
    }
  }
}
